ATNM Stock — Actinium Pharmaceuticals Inc. (Delaware): Cash, EV, Pipeline

Share price

$1.22

Market cap

$38.4M

Cash

$36.5M

Enterprise value

$1.9M

Balance sheet

Cash	$36.5M
Debt	$0.0M
Net cash	$36.5M
Enterprise value	$1.9M
Basic shares	31.4M shares
Fully diluted shares	40.7M shares
Fully diluted market cap	$49.7M
Cash per share	$1.16

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ATNM daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 15 - Apr 26	131I-apamistamab	Phase 3	Acute Leukemia; Myeloid Leukemia; Acute Myelogenous Leukemia	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Actimab-A

Phase 2/3 · Active Modality: radiopharmaceutical (Ac-225)

Target CD33

Partnerships National Cancer Institute (NCI): partnership for AML/MDS development

Indications

Relapsed/refractory AML (Phase 2/3)
High-risk MDS (Stage not disclosed)
Solid tumors (HNSCC, NSCLC, glioblastoma) (Stage not disclosed)

Status note FDA-aligned Phase 2/3 trial design in expanded R/R AML; Phase 1b + CLAG-M completed. Phase 1b basket with pembrolizumab/nivolumab in solid tumors planned. Company actively seeking strategic partnerships to advance late-stage hematology programs.

Iomab-B

Phase 3 · Active Modality: radiopharmaceutical (I-131)

Aliases I-131 apamistamab

Target CD45

Partnerships Immedica: exclusive EUMENA commercialization rights, $35M upfront; Immedica will not pursue regulatory approval in licensed territories (upfront recognized as revenue Jun 2026). Fred Hutchinson Cancer Research Center: exclusive apamistamab antibody license; $1M FDA-approval milestone; 2% royalties

Indications

Bone marrow transplant conditioning (R/R AML) (Phase 3)

Status note SIERRA Phase 3 trial completed. Company actively seeking strategic partner for pivotal development and commercialization. Securities litigation re SIERRA disclosures pending (motion to dismiss, as of filing).

Iomab-ACT

Stage not disclosed · Active Modality: radiopharmaceutical

Target CD45

Indications

Conditioning for cell & gene therapies (NHL) (Stage not disclosed)

Status note Targeted conditioning agent for cell & gene therapies; clinical trials executed across Actimab-A/Iomab-ACT programs per filing, but stage for Iomab-ACT not specified.

ATNM-400

Preclinical · Active Modality: radiopharmaceutical (licensed monoclonal antibody)

Target not disclosed (novel non-PSMA antigen)

Partnerships Undisclosed third party: exclusive worldwide license (Jun 25, 2024) for radiopharmaceutical products incorporating a licensed monoclonal antibody; upfront + development/regulatory/commercial milestones and royalties (amounts not disclosed)

Indications

mCRPC (Preclinical)
NSCLC (Preclinical)
Breast cancer (HR+/HER2-, HER2+, TNBC) (Preclinical)

Status note Targets a novel non-PSMA antigen (name not disclosed). Preclinical translational data presented at AACR Apr 21, 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	131I-apamistamab
Lead indication	Acute Leukemia
Lead phase	Phase 3
Active trials	2
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07157514	Phase 3	Not yet recruiting	Sponsor	ATNM	—	Acute Leukemia; Myeloid Leukemia; Acute Myelogenous Leukemia	—
NCT02665065	Phase 3	Active, not recruiting	Sponsor	ATNM	—	Acute Myeloid Leukemia; Leukemia, Acute Myeloid; Myeloid Leukemia, Acute	—
NCT06768905	Phase 2	Recruiting	Collaborator	University of Texas Southwestern Medical Center	—	Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma	—
NCT07015684	Phase 1	Recruiting	Collaborator	Columbia University	—	Sickling Disorder Due to Hemoglobin S	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Actinium Pharmaceuticals on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ATNM — Actinium Pharmaceuticals Inc. (Delaware)

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials